Advertisement

Topics

Forteo Reduced Risk for New Vertebral and Clinical Fractures in Postmenopausal Women with Severe Osteoporosis

10:08 EST 10 Nov 2017 | Speciality Pharma Journal

INDIANAPOLIS, Nov. 9, 2017 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) today announced new data showing that treatment with FORTEO® for 24 months was associated with significantly fewer vertebral and clinical fractures (a composite of painful vertebral and non-vertebral fractures) compared with risedronate, a widely used oral bisphosphonate, in postmenopausal women with severe osteoporosis

Original Article: Forteo Reduced Risk for New Vertebral and Clinical Fractures in Postmenopausal Women with Severe Osteoporosis

NEXT ARTICLE

More From BioPortfolio on "Forteo Reduced Risk for New Vertebral and Clinical Fractures in Postmenopausal Women with Severe Osteoporosis"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Women's Health
Women's Health - key topics include breast cancer, pregnancy, menopause, stroke Follow and track Women's Health News on BioPortfolio: Women's Health News RSS Women'...

Rheumatology
Arthritis Fibromyalgia Gout Lupus Rheumatic Rheumatology is the medical specialty concerned with the diagnosis and management of disease involving joints, tendons, muscles, ligaments and associated structures (Oxford Medical Diction...